Characteristics of patients given either nonmyeloablative or conventional conditioning regimens before allogeneic peripheral blood stem cell transplant
| . | Nonmyeloblative . | Conventional . |
|---|---|---|
| No. of patients | 40 | 67 |
| Age, years | ||
| Mean | 51 | 45 |
| Median | 53 | 46 |
| Range | 21-67 | 23-66 |
| Gender, no. of patients (%) | ||
| Male | 25 (62.5) | 44 (65.7) |
| Female | 15 (37.5) | 23 (34.3) |
| Disease, no. of patients (%) | ||
| AL | 6 (15.0) | 27 (40.3) |
| MM | 12 (30.0) | 1 (1.5) |
| CLL | 9 (22.5) | 1 (1.5) |
| MDS | 1 (2.5) | 9 (13.4) |
| CML | 1 (2.5) | 13 (19.4) |
| AMM | 1 (2.5) | 7 (10.4) |
| NHL/HD | 10 (25.0) | 9 (13.4) |
| Splenomegaly, no. of patients (%) | 7 (17.5) | 16 (23.9) |
| Preceding transfusions, No. of patients (%) | ||
| Platelet | 10 (25.0) | 17 (25.4) |
| RBCs | 12 (30.0) | 28 (41.8) |
| Average daily transfusion pretransplantation (units/day) | ||
| Platelet | 0.162 | 0.178 |
| RBCs | 0.048 | 0.089 |
| Conditioning regimens, no. of patients (%) | ||
| TBI (2 Gy) | 30 (75.0) | — |
| TBI (2 Gy) + fludarabine | 10 (25.0) | — |
| TBI (12-14.4 Gy) + busulfan | — | 10 (14.9) |
| TBI (12-14.4 Gy) + cyclophosphamide | — | 19 (28.4) |
| Busulfan + cyclophosphamide | — | 37 (55.2) |
| Postgrafting immunosuppression, no. of patients (%) | ||
| MMF + CSP | 40 (100) | 4 (6.0) |
| MTX + CSP | — | 63 (94.0) |
| No. of CD34+ cells, × 106/kg | ||
| Median | 10.4 | 7.7 |
| Minimum | 1.7 | 2.7 |
| Maximum | 30.4 | 27.6 |
| ABO compatibility, no. of patients (%) | ||
| Compatible | 21 (52.5) | 40 (59.7) |
| Incompatible, minor | 12 (30.0) | 10 (14.9) |
| Incompatible, major | 5 (12.5) | 14 (20.9) |
| Incompatible, bidirectional | 2 (5.0) | 3 (4.5) |
| . | Nonmyeloblative . | Conventional . |
|---|---|---|
| No. of patients | 40 | 67 |
| Age, years | ||
| Mean | 51 | 45 |
| Median | 53 | 46 |
| Range | 21-67 | 23-66 |
| Gender, no. of patients (%) | ||
| Male | 25 (62.5) | 44 (65.7) |
| Female | 15 (37.5) | 23 (34.3) |
| Disease, no. of patients (%) | ||
| AL | 6 (15.0) | 27 (40.3) |
| MM | 12 (30.0) | 1 (1.5) |
| CLL | 9 (22.5) | 1 (1.5) |
| MDS | 1 (2.5) | 9 (13.4) |
| CML | 1 (2.5) | 13 (19.4) |
| AMM | 1 (2.5) | 7 (10.4) |
| NHL/HD | 10 (25.0) | 9 (13.4) |
| Splenomegaly, no. of patients (%) | 7 (17.5) | 16 (23.9) |
| Preceding transfusions, No. of patients (%) | ||
| Platelet | 10 (25.0) | 17 (25.4) |
| RBCs | 12 (30.0) | 28 (41.8) |
| Average daily transfusion pretransplantation (units/day) | ||
| Platelet | 0.162 | 0.178 |
| RBCs | 0.048 | 0.089 |
| Conditioning regimens, no. of patients (%) | ||
| TBI (2 Gy) | 30 (75.0) | — |
| TBI (2 Gy) + fludarabine | 10 (25.0) | — |
| TBI (12-14.4 Gy) + busulfan | — | 10 (14.9) |
| TBI (12-14.4 Gy) + cyclophosphamide | — | 19 (28.4) |
| Busulfan + cyclophosphamide | — | 37 (55.2) |
| Postgrafting immunosuppression, no. of patients (%) | ||
| MMF + CSP | 40 (100) | 4 (6.0) |
| MTX + CSP | — | 63 (94.0) |
| No. of CD34+ cells, × 106/kg | ||
| Median | 10.4 | 7.7 |
| Minimum | 1.7 | 2.7 |
| Maximum | 30.4 | 27.6 |
| ABO compatibility, no. of patients (%) | ||
| Compatible | 21 (52.5) | 40 (59.7) |
| Incompatible, minor | 12 (30.0) | 10 (14.9) |
| Incompatible, major | 5 (12.5) | 14 (20.9) |
| Incompatible, bidirectional | 2 (5.0) | 3 (4.5) |
AL includes acute lymphocytic leukemia, acute myelogenous leukemia, refractory anemia with excess of blasts, refractory anemia with excess of blasts in transformation; MM, multiple myeloma, amyloidosis; CLL, chronic lymphocytic leukemia, prolymphocytic leukemia, Waldenström disease; MDS, refractory anemia, refractory anemia with ringed sideroblasts, chronic myelomonocytic leukemia; CML, chronic myelogenous leukemia in chronic phase; AMM, agnogenic myeloid metaplasia, myelofibrosis; NHL/HD, non-Hodgkin lymphoma, Hodgkin disease; TBI, total body irradiation; CSP, cyclosporine; MMF, mycophenolate mofetil; and MTX, methotrexate.